Process development for improved Car-t production utilizing an automated perfusion stirred-tank bioreactor
February 6 – 10, 2022
Ex vivo genetically-modified cellular immunotherapies, such as chimeric antigen receptor T-cells (CAR-T), have generated significant clinical and commercial outcomes due to their unparalleled response rates against refractory/relapsed blood cancers. However, the development and manufacture of these advanced therapies face a number of translational bottlenecks that must be addressed to ensure long-term commercial viability.
Please click Additional Files below to see the full abstract.
Tiffany Hood, Fern Slingby, Winfred Geis, Viktor Sander, Nicola Bevan, Quentin Vicard, and Qasim A. Rafiq, "Process development for improved Car-t production utilizing an automated perfusion stirred-tank bioreactor" in "Advancing Manufacture of Cell and Gene Therapies VII", Sharon Brownlow, Cell & Gene Therapy Catapult, UK; Sean Palecek, University of Wisconsin, USA; Damian Marshall, Achilles Therapeutics, UK; Fernanda Masri, Cell & Gene Therapy Catapult, UK Eds, ECI Symposium Series, (2022). https://dc.engconfintl.org/cellgenetherapies_vii/2